Accelerated partial breast irradiation using once-daily fractionation: analysis of 312 cases with four years median follow-up

• Published in: Radiation oncology (London, England) England), 2012-02, Vol.7 (1), p.17-17, Article 17
• Main Authors: Shaikh, Arif Y, LaCombe, Michael A, Du, Hongyan, Raghavan, Vathsala T, Nanda, Ranjeev K, Bloomer, William D
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Analysis; APBI; Bone density; breast; Breast cancer; Breast Neoplasms - pathology; Breast Neoplasms - radiotherapy; Breast Neoplasms - surgery; Cancer therapies; Carcinoma in situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast - pathology; Carcinoma, Ductal, Breast - radiotherapy; Carcinoma, Ductal, Breast - surgery; Carcinoma, Intraductal, Noninfiltrating - pathology; Carcinoma, Intraductal, Noninfiltrating - radiotherapy; Carcinoma, Intraductal, Noninfiltrating - surgery; Carcinoma, Lobular - pathology; Carcinoma, Lobular - radiotherapy; Carcinoma, Lobular - surgery; Care and treatment; DCIS; Dose Fractionation; Drug dosages; Female; Follow-Up Studies; Humans; IMRT; invasive lobular carcinoma; Mammography; Middle Aged; Neoplasm Grading; Prognosis; Radiation therapy; Radioisotope brachytherapy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Review boards; Statistical methods; Studies
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/1748-717X-7-17

There are limited data on accelerated partial breast irradiation (APBI) using external beam techniques. Moreover, there are recent reports of increased fibrosis and unacceptable cosmesis with APBI using external beam with BID fractionation. We adopted a once daily regimen of APBI with fractionation similar to that shown to be effective in a Canadian randomized trial of whole breast irradiation. It is unclear whether patients with DCIS or invasive lobular carcinoma (ILC) are suitable for APBI. The retrospective cohort included 310 patients with 312 tumors of T1-T2N0-N1micM0 invasive ductal carcinoma (IDC), ILC, or Tis (DCIS) treated with APBI via external beam. Most patients were treated using IMRT with 16 daily fractions of 270 cGy to a dose of 4320 cGy. The target volume included the lumpectomy cavity plus 1.0 cm to account for microscopic disease and an additional 0.5 to 1.0 cm for setup uncertainty and breathing motion. Ipsilateral breast failure (IBF) was pathologically confirmed as a local failure (LF) or an elsewhere failure (EF). Median follow-up was 49 months. Among the 312 cases, 213 were IDC, 31 ILC, and 68 DCIS. Median tumor size was 1.0 cm. There were 9 IBFs (2.9%) including 5 LFs and 4 EFs. The IBF rates among patients with IDC, ILC, and DCIS were 2.4%, 3.2%, and 4.4%, respectively, with no significant difference between histologies. When patients were analyzed by the ASTRO APBI consensus statement risk groups, 32% of treated cases were considered suitable, 50% cautionary, and 18% unsuitable. The IBF rates among suitable, cautionary, and unsuitable patients were 4.0%, 2.6%, and 1.8%, respectively, with no significant difference between risk groups. Acute skin reactions were rare and long-term cosmetic outcome was very good to excellent. External beam APBI with once daily fractionation has a low rate of IBF consistent with other published APBI studies. The ASTRO risk stratification did not differentiate a subset of patients with a higher rate of IBF. APBI may be an appropriate treatment for women with DCIS and ILC.